Donald W. DeGolyer

CIK: 0001583098

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (75.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EBS

Emergent BioSolutions Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

EBS
Emergent BioSolutions Inc.
Oct 7, 2026
Sale(S)
Direct
17.8K shares at avg. $7.09$126K
EBS
Emergent BioSolutions Inc.
May 1, 2026
Sale(S)
Direct
954 shares at avg. $8.96$9K
EBS
Emergent BioSolutions Inc.
May 1, 2026
Sale(S)
Direct
14.5K shares at avg. $8.36$121K
EBS
Emergent BioSolutions Inc.
Apr 30, 2026
Award(A)
Direct
25.3K shares-
EBS
Emergent BioSolutions Inc.
Nov 10, 2025
Sale(S)
Direct
17.8K shares at avg. $10.54$188K
EBS
Emergent BioSolutions Inc.
Aug 12, 2025
Sale(S)
Direct
7.8K shares at avg. $8.65$68K
EBS
Emergent BioSolutions Inc.
Apr 30, 2025
Award(A)
Direct
34.4K shares-
EBS
Emergent BioSolutions Inc.
Nov 12, 2024
Sale(S)
Direct
25K shares at avg. $10.91$273K

		Type	Shares	Price		Ownership
Oct 7, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	17,800	$7.09	$126,202	Direct
May 1, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	954	$8.96	$8,548	Direct
May 1, 2026	EBS Emergent BioSolutions Inc.	Sale(S)	14,527	$8.36	$121,446	Direct
Apr 30, 2026	EBS Emergent BioSolutions Inc.	Award(A)	25,344	-	$0	Direct
Nov 10, 2025	EBS Emergent BioSolutions Inc.	Sale(S)	17,801	$10.54	$187,623	Direct
Aug 12, 2025	EBS Emergent BioSolutions Inc.	Sale(S)	7,844	$8.65	$67,831	Direct
Apr 30, 2025	EBS Emergent BioSolutions Inc.	Award(A)	34,403	-	-	Direct
Nov 12, 2024	EBS Emergent BioSolutions Inc.	Sale(S)	25,000	$10.91	$272,750	Direct

1-8 of 8 transactions

About DeGolyer Donald W

DeGolyer Donald W (SEC CIK 0001583098) files insider reports with the SEC as Director of Emergent BioSolutions Inc. (EBS).

Signal8 holds 6 ownership filings by DeGolyer Donald W, all Form 4s, filed between Nov 14, 2024 and Oct 7, 2026. Those filings report 8 transactions, from Nov 12, 2024 to Oct 7, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DeGolyer Donald W's filings is in GAITHERSBURG, MD.

Recent filings by DeGolyer Donald W

Oct 7, 2026: Open-market sale of EBS shares (Form 4, code S).
May 1, 2026: Open-market sales of EBS shares (2 lines, Form 4, code S).
Apr 30, 2026: Grant or award of EBS shares (Form 4, code A).
Nov 10, 2025: Open-market sale of EBS shares (Form 4, code S).
Aug 12, 2025: Open-market sale of EBS shares (Form 4, code S).

Other insiders filing for Emergent BioSolutions Inc. (EBS)

Williams Paul Anthony, SVP, Products Business
Duatschek Stephanie, EVP, CGO
LINDAHL RICHARD S, EVP, Chief Financial Officer
Glessner Coleen, EVP, Quality & Ethics, and CPL
Hartzel William, SVP, Bioservices
Dayal Sujata Tyagi, Director

How to read Form 4 transaction codes